relation to e Dose) study drug) Female, 34 None / None 3 Cycles cell 775 days 928 days a (264 mg) carcinoma (25 months) (~31 (Grade 2, months) serious, not related) 3 Cycles cell 1946 days 1172 days (264 mg) carcinoma (~63 (~39 (Grade 3, months) months) serious, related) 3 Cycles Thyroid 2021 days 1247 (264 mg) cancer (70 months) (41 3, serious, months) related) Female, 32 None / None 2 cycles Vulvar 637 days 265 days (194 mg) cancer 0 (21 months) (9 months) (Grade 3, serious, related) Female, 46 None / None 1 cycle (120 cell 155 days 155 days mg) carcinoma (5 months) (5 months) (Grade 3, serious, related) Female, 29 None / None 2 cycles Breast 816 days 434 days (192 mg) cancer (27 months) (14 (Grade 2, months) serious, related) Female, 44 None / family 2 Cycles Breast 943 days 527 days history of breast (192 mg) cancer (31 months) (17 cancer (Grade 3, months) serious, not related) Female, 28 None / None 2 Cycles Cervix 695 days 314 days (192 mg) carcinoma (23 months) (10 (grade 1, months) serious, not related)
Dose) relation to study drug) Female, 34 a None / None 3 Cycles (264 mg) cell carcinoma (Grade 2, serious, not related) 775 days (25 months) 928 days (~31 months) 3 Cycles (264 mg) cell carcinoma (Grade 3, serious, related) 1946 days (~63 months) 1172 days (~39 months) 3 Cycles (264 mg) Thyroid cancer 3, serious, related) 2021 days (70 months) 1247 (41 months) Female, 32 None / None 2 cycles (194 mg) Vulvar cancer 0 (Grade 3, serious, related) 637 days (21 months) 265 days (9 months) Female, 46 None / None 1 cycle (120 mg) cell carcinoma (Grade 3, serious, related) 155 days (5 months) 155 days (5 months) Female, 29 None / None 2 cycles (192 mg) Breast cancer (Grade 2, serious, related) 816 days (27 months) 434 days (14 months) Female, 44 None / family history of breast cancer 2 Cycles (192 mg) Breast cancer (Grade 3, serious, not related) 943 days (31 months) 527 days (17 months) Female, 28 None / None 2 Cycles (192 mg) Cervix carcinoma (grade 1, serious, not related) 695 days (23 months) 314 days (10 months) e
auspar-alemtuzumab-140204.docx